It has recently been reported that imatinib and nilotinib treatment leads to activation of MEK and ERK in several human tumour cell lines3, and ERK signalling has been implicated in meditating signalling pathways required for migration of glioma cells21, 22. Here, MAP2K7 is linked to central nervous system cancer.